 | | Vol. 12.47 – 11 December, 2020 |
| |
|
|
| Scientists developed immune-stimulating antibody conjugates comprising a TLR7/8 dual agonist conjugated to tumor-targeting antibodies.
[Nature Cancer] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers generated a conditional triple-H1-knockout mouse strain and depleted H1 in hematopoietic cells. H1 depletion in T cells led to de-repression of T cell activation genes, a process that mimicked normal T cell activation.
[Nature] |
|
|
|
| Investigators demonstrated that high-fat diet-induced obesity impaired CD8+ T cell function in the murine tumor microenvironment, accelerating tumor growth.
[Cell] |
|
|
|
| The authors report that CRISPR–RfxCas13d could effectively discriminate circular RNAs from mRNAs by using guide RNAs targeting sequences spanning back-splicing junction sites featured in RNA circles.
[Nature Methods] |
|
|
|
| Researchers showed that Ataxia Telangiectasia Mutated (ATM) inhibition could potentiate immune checkpoint blockade therapy by promoting cytoplasmic leakage of mitochondrial DNA (mtDNA) and activation of the cGAS/STING pathway.
[Journal of Clinical Investigation] |
|
|
|
| Investigators demonstrated that tumor-derived UBR5, an E3 ligase overexpressed in human ovarian cancer (OC) associated with poor prognosis, was essential for OC progression principally by promoting tumor-associated macrophage recruitment and activation via key chemokines and cytokines.
[Nature Communications] |
|
|
|
| Scientists showed that B7-CD28 co-stimulation and B7 expression by specific antigen-presenting cell types were required for clonal deletion and for regulatory T cell generation from endogenous tissue-restricted antigen-specific thymocytes.
[Nature Communications] |
|
|
|
| To assess the relevance of autophagy to T cell allo-immunity, the authors generated T cell specific ATG5 knock-out mice. Deficiency of ATG5 dependent autophagy reduced T cell proliferation, increased apoptosis following in vitro and in vivo allo-stimulation.
[Cancer Research] |
|
|
|
| The authors investigated roles of SKIL in tumorigenesis and immune escape of non-small-cell lung cancer (NSCLC). SKIL expression levels in NSCLC cell line, clinical sample, and adjacent normal tissue were measured by quantitative PCR, western blot, or immunohistochemistry.
[Cell Death & Disease] |
|
|
|
| Scientists assessed the effects that menstrual blood-derived stromal cells had on the recruitment of macrophages and other innate immune cells in two mouse models of acute inflammation, a thioglycollate-elicited peritonitis model and a monobacterial sepsis model.
[Scientific Reports] |
|
|
|
| Forcing NLRC5 expression promoted Vγ9Vδ2 T cell-mediated killing of tumor cells in a BTN3A-dependent manner.
[iScience] |
|
|
|
| Oral administration of β-elemene, contained in various foodstuffs, downregulated expressions of inflammatory cytokines and increased Foxp3+CD4+ T cells in adipose tissue of obese mice.
[iScience] |
|
|
|
|
| Scientists provide an overview of what is known about natural killer (NK) tumor infiltration and surveillance and about the mechanisms by which NK cells become dysfunctional.
[Cancer Discovery] |
|
|
|
| The authors discuss natural killer cells’ cytotoxicity and modulation function in gastrointestinal cancer and the current application in clinical therapy.
[Oncogene] |
|
|
|
|
| Fate Therapeutics, Inc. announced positive interim data from the company’s dose escalation Phase I study of FT516 in combination with rituximab for patients with relapsed/refractory B-cell lymphoma.
[Fate Therapeutics, Inc.] |
|
|
|
| The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application to the FDA seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
[Janssen LLC] |
|
|
|
|
| January 19 – 21, 2021
Virtual |
|
|
|
|
|
| | Karolinska Institutet – Solna, Sweden |
|
|
|
| | Rubius Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| | Queen’s University – Kingston, Ontario, Canada |
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| | H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
